Please assess the completion status of the following clinical trial:

Trial Title: TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Must have histologically confirmed DLBCL, including de novo disease or transformed disease from indolent NHL.~   a. High-grade B-cell lymphoma (BCL) with MYC and BCL-2 and/or BCL-6 translocations (double-hit DLBCL under DLBCL, not otherwise specified \[NOS\], based on the 2008 World Health Organization \[WHO\] classification criteria) is not eligible for this study.~2. Local pathology review for histological confirmation; A formalin-fixed, paraffin-embedded (FFPE) tumor block or appropriately stained slides from a fresh biopsy is required.~3. Relapsed or refractory to greater than or equal to (\>=) 2 prior lines of chemotherapy based on standard of care with certain requirements for prior therapy.~4. Documented investigator-assessed relapse or progression after the last treatment is required if the participant responded and then progressed on the prior treatment.~5. Measurable disease per IWG 2007 criteria.~6. Eastern Cooperative Oncology Group (ECOG) performance status less than (\<) 2.~7. Life expectancy of greater than (\>) 3 months.~8. Adequate organ function, including the following:~   1. Bone marrow reserve: absolute neutrophil count (ANC) \>=1000/microliter (μL), platelet count \>=75,000/μL (\>=50,000/μL for participants with bone marrow involvement), and hemoglobin \>=8 gram per deciliter (g/dL).~  2. Hepatic: total bilirubin less than or equal to (\<=) 1.5 times the upper limit of the normal range (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<=2.5\*ULN.~  3. Renal: creatinine clearance \>=60 milliliter per minute (mL/min).~  4. Others:~      * Lipase \<=1.5\*ULN and amylase \<=1.5\*ULN with no clinical symptoms suggestive of pancreatitis or cholecystitis.~     * Blood pressure \<=Grade 1 (hypertensive participants are permitted if their blood pressure is controlled to \<=Grade 1 by hypertensive medications.~     * Glycosylated hemoglobin is \<=6.5% hyperglycemic participants permitted if glucose is well controlled by antihyperglycemic medication).~Exclusion Criteria:~1. Central nervous system (CNS) lymphoma; active brain or leptomeningeal metastases.~2. Known human immunodeficiency virus (HIV)-related malignancy.~3. Systemic anticancer treatment (including investigational agents) less than 3 weeks before the first dose of study treatment (\<=4 weeks for antibody-based therapy including unconjugated antibody, antibody-drug conjugate, and bi-specific T-cell engager agents; \<=8 weeks for cell-based therapy or anti-tumor vaccine).~4. Radiotherapy less than 3 weeks before the first dose of study treatment. If prior radiotherapy occurred \<4 to 6 weeks before study start, as radiated lesions cannot be reliably assessed by fluorodeoxyglucose-positron emission tomography (FDG-PET), nonradiated target lesions are required for eligibility, and prior radiotherapy information must be submitted to the IRC.~5. Known HIV positive, hepatitis B surface antigen positive or known or suspected active hepatitis C infection.~6. Prior autologous stem cell transplant (ASCT) within 6 months or prior ASCT at any time without full hematopoietic recovery before Cycle 1 Day 1, or allogeneic stem cell transplant any time.~7. Participants with certain cardiovascular conditions are excluded.~8. Major surgery within 14 days before the first dose of study drug or incomplete recovery from any complications from surgery.~9. Systemic infection requiring parenteral antibiotic therapy or other serious infection (bacterial, fungal, or viral) within 21 days before the first dose of study drug.~10. Treatment with high-dose corticosteroids for anticancer purposes within 7 days before the first dose of TAK-659.~11. Participants with another malignancy within 2 years of study start. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection and are considered disease-free at the time of study entry.~12. Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of TAK-659.~13. Received medications, supplements, or food/beverages that are P-glycoprotein (P-gp) inhibitors or inducers or strong cytochrome P450 (CYP) 3A inhibitors or inducers within a certain timeframe prior to the first dose of study drug. Depending on the substance, the washout period for P-gp inhibitors or inducers or strong CYP3A inhibitors or inducers will be either 7 days or 5 times the half-life (half-life is related to the time required for elimination from the body). The washout period for grapefruit containing food or beverages is 5 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A: TAK-659 100 mg (Type: EXPERIMENTAL): TAK-659 100 mg tablet, orally, once daily (QD), during each 28-days cycle (median exposure was 41 days).
- Cohort B: TAK-659 Ramp-up Dosing (Type: EXPERIMENTAL): TAK-659 60-100 mg tablet, orally, QD, dose based on safety and tolerability during each 28-days cycle (median exposure was 28 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy